BlueRock Therapeutics’ #iPSC-derived cell therapy lemiretprocel (OpCT-001) has received orphan drug designation from both the FDA and EMA for inherited retinal diseases.
Now in Phase 1/2a testing for retinitis pigmentosa, Usher syndrome & cone-rod dystrophies. #iPSC #CellTherapy
